|
|
Article: Inspire and FAES Farma Announce Licensing Agreement for New Oral Antihistamine to Target Allergy Market in United States and Canada.
- Article from:
- Business Wire
- Article date:
- November 1, 2006
|
Copyright informationCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Inspire Expands Allergy Product Portfolio with Phase 3 Compound
Inspire Will Host Conference Call on November 1 at 10:00 am ET
DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) and FAES Farma, S.A. (IBEX: FAE) announced today the signing of a licensing agreement for the U.S. and Canadian development and commercialization of bilastine, a Phase 3 oral antihistamine compound for the treatment or prevention of allergic rhinitis, a condition affecting approximately 40 million people in the United States.
Under the terms of the agreement, Inspire has acquired exclusive rights to further develop and commercialize oral formulations of bilastine in the United ...